| Symbol | MRKR |
|---|---|
| Name | MARKER THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 3200 SOUTHWEST FREEWAY,SUITE2500, HOUSTON, Texas, 77027, United States |
| Telephone | +1 713 400-6400 |
| Fax | — |
| — | |
| Website | https://www.markertherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001094038 |
| Description | Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. Additional info from NASDAQ: |
2026-05-04 20:30
(99% Neutral) MARKER THERAPEUTICS, INC. (MRKR) Announces Regulatory Update
Read more
2026-03-18 21:31
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
Read more
2026-03-10 18:00
New Form PRE 14A - Marker Therapeutics, Inc. <b>Filed:</b> 2026-03-10 <b>AccNo:</b> 0001104659-26-025917 <b>Size:</b> 2 MB
Read more
2026-01-05 12:00
Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer
Read more
2025-11-19 21:10
Director Eansor Norman David 🟢 acquired 221.7K shares (2 derivative) of Marker Therapeutics, Inc. (MRKR) at $0.95 Transaction Date: Nov 17, 2025 | Filing ID: 000003
Read more
2025-11-19 21:01
Director ELMS STEVE 🟢 acquired 221.7K shares (2 derivative) of Marker Therapeutics, Inc. (MRKR) at $0.95 Transaction Date: Nov 17, 2025 | Filing ID: 114081
Read more
2025-11-17 21:23
New Form SCHEDULE 13D/A - Marker Therapeutics, Inc. Filed: 2025-11-17 AccNo: 0001072613-25-000858 Size: 79 KB
Read more
2025-11-15 01:09
New Form SCHEDULE 13G/A - Marker Therapeutics, Inc. Filed: 2025-11-14 AccNo: 0001172661-25-005191 Size: 11 KB
Read more
2025-11-14 12:20
(30% Negative) MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 2025 Financial Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06549751 | MT-601 Administered To Patients With Locally Advanced Unresectable or Metastati… | Phase1 | Pancreas Cancer | Not_Yet_Recruiting | 2026-07-16 | 2028-09-16 | ClinicalTrials.gov |
| NCT07391397 | Assessing PFAS Exposure for Better Health | Na | Environmental Health Effects | Completed | 2025-09-01 | 2026-03-03 | ClinicalTrials.gov |
| NCT07461857 | Minority-focused Environmental Health Education and Tracking Pilot Study | Na | Environmental Exposure | Completed | 2025-09-01 | 2026-02-20 | ClinicalTrials.gov |
| NCT07560579 | Weight Loss and Endocrine Disrupting Chemicals (EDCs): Lifestyle Interventions … | Na | Obesity &Amp;Amp;Amp; Overweight | Active_Not_Recruiting | 2025-08-18 | 2026-09-01 | ClinicalTrials.gov |
| NCT07013123 | Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Con… | Phase3 | Severe Asthma | Not_Yet_Recruiting | 2025-07-15 | 2029-08-18 | ClinicalTrials.gov |
| NCT06993142 | Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage | Na | Parkinson Disease | Not_Yet_Recruiting | 2025-07-01 | 2029-06-30 | ClinicalTrials.gov |
| NCT06552416 | Safety of MT-401-OTS in Patients With Relapsed AML or MDS | Phase1 | Acute Myeloid Leukemia, in Relapse | Recruiting | 2025-06-16 | 2029-09-01 | ClinicalTrials.gov |
| NCT06614855 | A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumoral… | Phase1 | Glioblastoma | Active_Not_Recruiting | 2025-06-02 | 2028-01-01 | ClinicalTrials.gov |
| NCT06703632 | Evaluation of PreveCol's Efficiency As a Second Line Method for the Early Color… | Na | Screening for Colon Cancer | Recruiting | 2025-01-14 | 2025-12-01 | ClinicalTrials.gov |
| NCT06864377 | Ventral Hernia Improvement of Treatment and Life | — | Incisional Hernia | Enrolling_By_Invitation | 2025-01-01 | 2027-10-31 | ClinicalTrials.gov |
| NCT06450951 | A Personalized Biomonitoring and Report-back Intervention to Reduce Exposure to… | Na | Environmental Exposure | Active_Not_Recruiting | 2024-05-23 | 2026-05-31 | ClinicalTrials.gov |
| NCT05872867 | Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors an… | Phase1 | Advanced Solid Tumor | Unknown | 2024-03-14 | 2026-02-22 | ClinicalTrials.gov |
| NCT06193252 | Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-Netherlands | Na | Parkinson Disease | Recruiting | 2024-01-15 | 2027-12-01 | ClinicalTrials.gov |
| NCT06889883 | Development and Validation of a Blood Test for Early Diagnosis of Colorectal Ca… | — | Colorectal Carcinoma | Recruiting | 2023-06-06 | 2025-12-31 | ClinicalTrials.gov |
| NCT06889844 | Observational Cross-reactivity Study for Colorectal Cancer Diagnosis | — | Colorectal Cancer | Recruiting | 2023-04-17 | 2025-12-01 | ClinicalTrials.gov |
| NCT05798897 | Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory … | Phase1 | Non-Hodgkin Lymphoma, Adult | Recruiting | 2023-01-02 | 2028-02-28 | ClinicalTrials.gov |
| NCT04928703 | Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers | Early_Phase1 | Healthy | Completed | 2022-05-26 | 2022-12-12 | ClinicalTrials.gov |
| NCT05671744 | Fetal Cell Analysis From Maternal Blood | Na | Prenatal Screening | Unknown | 2021-11-22 | 2023-09-01 | ClinicalTrials.gov |
| NCT04904601 | Freeze-dried Kale to Reduce Metabolic Risk in Saudi Subjects | Na | Obesity | Completed | 2021-09-15 | 2022-09-28 | ClinicalTrials.gov |
| NCT04801095 | A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors | Phase1 | Advanced Solid Tumor | Unknown | 2021-07-14 | 2025-08-08 | ClinicalTrials.gov |
| NCT04927130 | Retrospective Comparative in Vitro Case-controlled Study of the Liquid Biopsy T… | — | Breast Neoplasm Female | Unknown | 2021-06-16 | 2021-12-31 | ClinicalTrials.gov |
| NCT04890340 | In Vitro Study of the Liquid Biopsy Test System of the Diagnostic Value, in Wom… | — | Breast Neoplasms | Unknown | 2021-05-21 | 2021-12-31 | ClinicalTrials.gov |
| NCT04511130 | Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant | Phase2 | Acute Myeloid Leukemia | Terminated | 2020-10-14 | 2024-03-01 | ClinicalTrials.gov |
| NCT04358003 | Plasma Adsorption in Patients With Confirmed COVID-19 | Na | Respiratory Failure | Completed | 2020-05-20 | 2022-04-01 | ClinicalTrials.gov |
| NCT04025502 | Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Hea… | — | Schizophrenia | Completed | 2019-10-07 | 2021-01-31 | ClinicalTrials.gov |
| NCT03500939 | Penumbral Rescue by Normobaric O2 Administration in Patients With Ischemic Stro… | Phase2 | Acute Ischemic Stroke | Terminated | 2019-08-01 | 2022-08-22 | ClinicalTrials.gov |
| NCT03815110 | Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification | — | Preeclampsia and Eclampsia | Completed | 2018-12-20 | 2022-10-01 | ClinicalTrials.gov |
| NCT06738511 | Validation of a Molecular Signature for Early Detection of Colorectal Cancer | Na | Colorectal Cancer Screening | Completed | 2018-05-28 | 2021-09-01 | ClinicalTrials.gov |
| NCT03651635 | MR-proADM and CT-proET-1 During ICU Treatment | — | Acute Phase Biomarkers | Completed | 2018-01-08 | 2019-02-28 | ClinicalTrials.gov |
| NCT03669198 | A Health Economic Evaluation of Using N-Terminal Pro Brain Natriuretic Peptide … | Na | Heart Failure | Completed | 2017-11-01 | 2018-05-31 | ClinicalTrials.gov |
| NCT02978222 | Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patien… | Phase2 | Platinum Sensitive Ovarian Cancer | Terminated | 2017-07-20 | 2020-01-15 | ClinicalTrials.gov |
| NCT02843529 | Evaluation of a Computerized Complex Instrumental Activities of Daily Living Ma… | Na | Alzheimer Disease | Completed | 2016-10-17 | 2020-02-21 | ClinicalTrials.gov |
| NCT02750826 | Breast Cancer WEight Loss Study (BWEL Study) | Phase3 | Breast Carcinoma | Active_Not_Recruiting | 2016-09-16 | 2030-05-30 | ClinicalTrials.gov |
| NCT02914782 | Investigation of Fluid- and Electrolyte Balance in Post Cardiac-surgery Patients | — | Electrolyte Imbalances | Completed | 2016-09-01 | 2022-10-01 | ClinicalTrials.gov |
| NCT03060109 | Fresh Intravenous Blood Samples for TBI Diagnostic Assay Development With Phili… | — | Traumatic Brain Injury | Terminated | 2016-06-21 | 2017-09-10 | ClinicalTrials.gov |
| NCT02764333 | TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 M… | Phase2 | Ovarian Cancer | Completed | 2016-05-06 | 2021-01-20 | ClinicalTrials.gov |
| NCT02593227 | Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negat… | Phase2 | Breast Cancer | Completed | 2016-04-01 | 2021-07-15 | ClinicalTrials.gov |
| NCT02541123 | Evaluation of Biomarker Kinetics After Mild Brain Injury Trauma | — | Traumatic Brain Injury | Completed | 2016-01-01 | 2017-02-28 | ClinicalTrials.gov |
| NCT02449850 | Preventing Atopic Dermatitis and ALLergies in Children | Na | Atopic Dermatitis | Active_Not_Recruiting | 2014-12-14 | 2044-06-01 | ClinicalTrials.gov |
| NCT02189525 | Evaluation of Mild TBI in Collegiate Athletes | — | Traumatic Brain Injury | Completed | 2014-08-01 | 2018-07-25 | ClinicalTrials.gov |
| NCT02269397 | Proof of Principle for a Diagnostic Blood Test of Recurrent Seizures | — | Epilepsy | Completed | 2013-07-01 | 2018-12-06 | ClinicalTrials.gov |
| NCT01909505 | Comparison of Salivary and Serum Free Testosterone in Normal and Hypogonadal Men | — | Known Androgen Deficiency | Unknown | 2013-06-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01857947 | Prognosis Value of Pro-adrenomedullin in Acute Exacerbations of COPD in ER | Na | Pulmonary Disease, Chronic Obstructive Patients Admitted in Emergency Department for Acute Exacerbation | Completed | 2013-03-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02390999 | Neurological Prognostication of Patients in Therapeutic Hypothermia After Cardi… | Na | Cardiac Arrest | Completed | 2013-03-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01426919 | Evaluation of Biomarkers of Traumatic Brain Injury | — | Traumatic Brain Injury | Completed | 2012-12-01 | 2017-07-01 | ClinicalTrials.gov |
| NCT01632332 | Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-… | Phase1 | HER2-positive Breast Cancer | Completed | 2012-07-09 | 2018-07-09 | ClinicalTrials.gov |
| NCT01858675 | Biomarkers Correlation With Volemia | Na | Cerebral Hemorrhage | Completed | 2012-03-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01472042 | A Evaluation Of Biomarkers Associated With Sports Induced Concussions In Colleg… | — | Traumatic Brain Injury | Completed | 2011-11-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT01334645 | Copeptin and Acute Coronary Syndrome Without ST-segment Elevation | Na | Chest Pain | Completed | 2011-03-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01786460 | Brain Injury Biomarkers in the General Population | — | Brain Injuries, Traumatic | Completed | 2011-01-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01227317 | BIOmarkers of Dyspnea IN Emergency Room | — | Severe Dyspnea | Completed | 2010-04-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01374880 | Diagnostic and Prognostic Value of New Biomarkers in Patients With Heart Disease | — | Heart Failure | Unknown | 2009-06-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01692353 | Cardiovascular Disease Biomarkers in Smokers and Moist Snuff Consumers | — | Cardiovascular Disease | Completed | 2008-09-01 | 2009-04-01 | ClinicalTrials.gov |
Total clinical trials: 53
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Education curriculum | Other | Approved | Environmental Exposure | COMPLETED | NCT07461857 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | COMPLETED | NCT07391397 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Education curriculum | Other | Approved | Environmental Exposure | COMPLETED | NCT07461857 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | COMPLETED | NCT07391397 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Education curriculum | Other | Approved | Environmental Exposure | COMPLETED | NCT07461857 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | COMPLETED | NCT07391397 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Education curriculum | Other | Approved | Environmental Exposure | COMPLETED | NCT07461857 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | COMPLETED | NCT07391397 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | COMPLETED | NCT07391397 |
| Education curriculum | Other | Approved | Environmental Exposure | COMPLETED | NCT07461857 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | COMPLETED | NCT07391397 |
| Education curriculum | Other | Approved | Environmental Exposure | COMPLETED | NCT07461857 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | COMPLETED | NCT07391397 |
| Education curriculum | Other | Approved | Environmental Exposure | COMPLETED | NCT07461857 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | COMPLETED | NCT07391397 |
| Education curriculum | Other | Approved | Environmental Exposure | COMPLETED | NCT07461857 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | COMPLETED | NCT07391397 |
| Education curriculum | Other | Approved | Environmental Exposure | COMPLETED | NCT07461857 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | COMPLETED | NCT07391397 |
| Education curriculum | Other | Approved | Environmental Exposure | COMPLETED | NCT07461857 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | COMPLETED | NCT07391397 |
| Education curriculum | Other | Approved | Environmental Exposure | COMPLETED | NCT07461857 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | COMPLETED | NCT07391397 |
| Education curriculum | Other | Approved | Environmental Exposure | COMPLETED | NCT07461857 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | COMPLETED | NCT07391397 |
| Education curriculum | Other | Approved | Environmental Exposure | COMPLETED | NCT07461857 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | COMPLETED | NCT07391397 |
| Education curriculum | Other | Approved | Environmental Exposure | COMPLETED | NCT07461857 |
| Educational curriculum | Other | Approved | Environmental Exposure | ACTIVE_NOT_RECRUITING | NCT06450951 |
| Urinary EDC metabolite testing | Other | Approved | Environmental Exposure | ACTIVE_NOT_RECRUITING | NCT06450951 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | COMPLETED | NCT07391397 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Environmental Exposure | ACTIVE_NOT_RECRUITING | NCT06450951 |
| Urinary EDC metabolite testing | Other | Approved | Environmental Exposure | ACTIVE_NOT_RECRUITING | NCT06450951 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | COMPLETED | NCT07391397 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Environmental Exposure | ACTIVE_NOT_RECRUITING | NCT06450951 |
| Urinary EDC metabolite testing | Other | Approved | Environmental Exposure | ACTIVE_NOT_RECRUITING | NCT06450951 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | COMPLETED | NCT07391397 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | COMPLETED | NCT07391397 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Environmental Exposure | ACTIVE_NOT_RECRUITING | NCT06450951 |
| Urinary EDC metabolite testing | Other | Approved | Environmental Exposure | ACTIVE_NOT_RECRUITING | NCT06450951 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | COMPLETED | NCT07391397 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Environmental Exposure | ACTIVE_NOT_RECRUITING | NCT06450951 |
| Urinary EDC metabolite testing | Other | Approved | Environmental Exposure | ACTIVE_NOT_RECRUITING | NCT06450951 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | COMPLETED | NCT07391397 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Environmental Exposure | ACTIVE_NOT_RECRUITING | NCT06450951 |
| Urinary EDC metabolite testing | Other | Approved | Environmental Exposure | ACTIVE_NOT_RECRUITING | NCT06450951 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | COMPLETED | NCT07391397 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Environmental Exposure | ACTIVE_NOT_RECRUITING | NCT06450951 |
| Urinary EDC metabolite testing | Other | Approved | Environmental Exposure | ACTIVE_NOT_RECRUITING | NCT06450951 |
| MT-601 dose 1200 million cells | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| MT-601 dose 800 million cells | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| MT-601 dose 400 million cells | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| MT-601 dose 200 million cells | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | COMPLETED | NCT07391397 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Environmental Exposure | ACTIVE_NOT_RECRUITING | NCT06450951 |
| Urinary EDC metabolite testing | Other | Approved | Environmental Exposure | ACTIVE_NOT_RECRUITING | NCT06450951 |
| MT-601 dose 1200 million cells | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| MT-601 dose 800 million cells | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| MT-601 dose 400 million cells | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| MT-601 dose 200 million cells | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| MT-601 dose 1200 million cells | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| MT-601 dose 800 million cells | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| MT-601 dose 400 million cells | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| MT-601 dose 200 million cells | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| MT-601 dose 1200 million cells | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| MT-601 dose 800 million cells | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| MT-601 dose 400 million cells | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| MT-601 dose 200 million cells | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| MT-601 dose 1200 million cells | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| MT-601 dose 800 million cells | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| MT-601 dose 400 million cells | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| MT-601 dose 200 million cells | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| MT-601 dose 1200 million cells | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| MT-601 dose 800 million cells | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| MT-601 dose 400 million cells | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| MT-601 dose 200 million cells | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| Blood draw at Days 0, 7, 14, and 21 | Other | Preclinical | Brain Injuries, Traumatic | COMPLETED | NCT01786460 |
| Blood draw at Days 0, 7, 14, and 21 | Other | Preclinical | Brain Injuries, Traumatic | COMPLETED | NCT01786460 |
| Standard of care | Other | Phase PHASE2 | Acute Ischemic Stroke | TERMINATED | NCT03500939 |
| Medical oxygen | Other | Phase PHASE2 | Acute Ischemic Stroke | TERMINATED | NCT03500939 |
| Standard of care | Other | Phase PHASE2 | Acute Ischemic Stroke | TERMINATED | NCT03500939 |
| Medical oxygen | Other | Phase PHASE2 | Acute Ischemic Stroke | TERMINATED | NCT03500939 |
| Prognostic value of Biomarkers | Other | Preclinical | Severe Dyspnea | COMPLETED | NCT01227317 |
| Prognostic value of Biomarkers | Other | Preclinical | Severe Dyspnea | COMPLETED | NCT01227317 |
| Copeptin | Other | Approved | Chest Pain | COMPLETED | NCT01334645 |
| Copeptin | Other | Approved | Chest Pain | COMPLETED | NCT01334645 |
| Biomarkers, red blood cells and plasma assessment | Other | Approved | Cerebral Hemorrhage | COMPLETED | NCT01858675 |
| Biomarkers, red blood cells and plasma assessment | Other | Approved | Cerebral Hemorrhage | COMPLETED | NCT01858675 |
| AECOPD Mr proADM | Other | Approved | Pulmonary Disease, Chronic Obstructive Patients Admitted in Emergency Department for Acute Exacerbation | COMPLETED | NCT01857947 |
| AECOPD Mr proADM | Other | Approved | Pulmonary Disease, Chronic Obstructive Patients Admitted in Emergency Department for Acute Exacerbation | COMPLETED | NCT01857947 |
| Subject's usual brand (UB) tobacco product | Other | Preclinical | Cardiovascular Disease | COMPLETED | NCT01692353 |
| Subject's usual brand (UB) tobacco product | Other | Preclinical | Cardiovascular Disease | COMPLETED | NCT01692353 |
| Subject's usual brand (UB) tobacco product | Other | Preclinical | Cardiovascular Disease | COMPLETED | NCT01692353 |
| Banyan Biomarkers | Other | Preclinical | Traumatic Brain Injury | COMPLETED | NCT01472042 |
| Banyan Biomarkers | Other | Preclinical | Traumatic Brain Injury | COMPLETED | NCT01472042 |
| 48 hours of therapeutic hypothermia | Other | Approved | Cardiac Arrest | COMPLETED | NCT02390999 |
| 48 hours of therapeutic hypothermia | Other | Approved | Cardiac Arrest | COMPLETED | NCT02390999 |
| Blood draw within 12 hours of injury | Other | Preclinical | Traumatic Brain Injury | TERMINATED | NCT03060109 |
| Blood draw within 12 hours of injury | Other | Preclinical | Traumatic Brain Injury | TERMINATED | NCT03060109 |
| Blood draw within 12 hours of injury | Other | Preclinical | Traumatic Brain Injury | TERMINATED | NCT03060109 |
| NT-Pro BNP | Other | Approved | Heart Failure | COMPLETED | NCT03669198 |
| NT-Pro BNP | Other | Approved | Heart Failure | COMPLETED | NCT03669198 |
| laboratory biomarker analysis | Other | Phase PHASE1 | HER2-positive Breast Cancer | COMPLETED | NCT01632332 |
| HER-2/neu peptide vaccine | Other | Phase PHASE1 | HER2-positive Breast Cancer | COMPLETED | NCT01632332 |
| Skin care | Other | Approved | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT02449850 |
| Food intervention | Other | Approved | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT02449850 |
| Skin care | Other | Approved | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT02449850 |
| Food intervention | Other | Approved | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT02449850 |
| Blood draw | Other | Preclinical | Traumatic Brain Injury | COMPLETED | NCT02541123 |
| Blood draw | Other | Preclinical | Traumatic Brain Injury | COMPLETED | NCT02541123 |
| Head CT scan and blood draw within 12 hours of injury | Other | Preclinical | Traumatic Brain Injury | COMPLETED | NCT01426919 |
| Head CT scan and blood draw within 12 hours of injury | Other | Preclinical | Traumatic Brain Injury | COMPLETED | NCT01426919 |
| Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System | Other | Preclinical | Schizophrenia | COMPLETED | NCT04025502 |
| ARNA Breast | Other | Preclinical | Breast Neoplasms | UNKNOWN | NCT04890340 |
| ARNA Breast | Other | Preclinical | Breast Neoplasms | UNKNOWN | NCT04890340 |
| Blood sampling for MR-proADM & CT-proET-1 | Other | Preclinical | Acute Phase Biomarkers | COMPLETED | NCT03651635 |
| Blood sampling for MR-proADM & CT-proET-1 | Other | Preclinical | Acute Phase Biomarkers | COMPLETED | NCT03651635 |
| Blood sampling for MR-proADM & CT-proET-1 | Other | Preclinical | Acute Phase Biomarkers | COMPLETED | NCT03651635 |
| ARNA Breast | Other | Preclinical | Breast Neoplasm Female | UNKNOWN | NCT04927130 |
| ARNA Breast | Other | Preclinical | Breast Neoplasm Female | UNKNOWN | NCT04927130 |
| High dose FRα vaccine | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02593227 |
| Cyclophosphamide | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02593227 |
| Low dose FRα vaccine | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02593227 |
| Durvalumab | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT02764333 |
| TPIV200 | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT02764333 |
| Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol) | Other | Approved | Respiratory Failure | COMPLETED | NCT04358003 |
| WM-S1-030 | Other | Phase PHASE1 | Advanced Solid Tumor | UNKNOWN | NCT04801095 |
| WM-S1-030 | Other | Phase PHASE1 | Advanced Solid Tumor | UNKNOWN | NCT04801095 |
| Observational Study | Other | Preclinical | Electrolyte Imbalances | COMPLETED | NCT02914782 |
| Observational Study | Other | Preclinical | Electrolyte Imbalances | COMPLETED | NCT02914782 |
| Observational Study | Other | Preclinical | Electrolyte Imbalances | COMPLETED | NCT02914782 |
| Adjuvant (GM-CSF) Alone | Other | Phase PHASE2 | Platinum Sensitive Ovarian Cancer | TERMINATED | NCT02978222 |
| FRα peptide plus Adjuvant (GM-CSF) | Other | Phase PHASE2 | Platinum Sensitive Ovarian Cancer | TERMINATED | NCT02978222 |
| Cell-based non-invasive prenatal testing | Other | Approved | Prenatal Screening | UNKNOWN | NCT05671744 |
| Cell-based non-invasive prenatal testing | Other | Approved | Prenatal Screening | UNKNOWN | NCT05671744 |
| Ketamine | Other | Phase EARLY_PHASE1 | Healthy | COMPLETED | NCT04928703 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumor | UNKNOWN | NCT05872867 |
| WM-A1-3389 | Other | Phase PHASE1 | Advanced Solid Tumor | UNKNOWN | NCT05872867 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumor | UNKNOWN | NCT05872867 |
| WM-A1-3389 | Other | Phase PHASE1 | Advanced Solid Tumor | UNKNOWN | NCT05872867 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumor | UNKNOWN | NCT05872867 |
| WM-A1-3389 | Other | Phase PHASE1 | Advanced Solid Tumor | UNKNOWN | NCT05872867 |
| MT-601 | Other | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| Altoida: neuropsychological, MRI, EEG and CSF biomarkers | Other | Approved | Alzheimer Disease | COMPLETED | NCT02843529 |
| colonoscopy | Other | Approved | Colorectal Cancer Screening | COMPLETED | NCT06738511 |
| stool sampling | Other | Approved | Colorectal Cancer Screening | COMPLETED | NCT06738511 |
| blood sampling | Other | Approved | Colorectal Cancer Screening | COMPLETED | NCT06738511 |
| colonoscopy | Other | Approved | Colorectal Cancer Screening | COMPLETED | NCT06738511 |
| stool sampling | Other | Approved | Colorectal Cancer Screening | COMPLETED | NCT06738511 |
| blood sampling | Other | Approved | Colorectal Cancer Screening | COMPLETED | NCT06738511 |
| Weight Loss Intervention | Other | Phase PHASE3 | Breast Carcinoma | ACTIVE_NOT_RECRUITING | NCT02750826 |
| Health Education Program | Other | Phase PHASE3 | Breast Carcinoma | ACTIVE_NOT_RECRUITING | NCT02750826 |
| Weight Loss Intervention | Other | Phase PHASE3 | Breast Carcinoma | ACTIVE_NOT_RECRUITING | NCT02750826 |
| Health Education Program | Other | Phase PHASE3 | Breast Carcinoma | ACTIVE_NOT_RECRUITING | NCT02750826 |
| Peas supplement | Other | Approved | Obesity | COMPLETED | NCT04904601 |
| Kale supplement | Other | Approved | Obesity | COMPLETED | NCT04904601 |
| Peas supplement | Other | Approved | Obesity | COMPLETED | NCT04904601 |
| Kale supplement | Other | Approved | Obesity | COMPLETED | NCT04904601 |
| Survey using a questionnaire. | Other | Approved | Screening for Colon Cancer | RECRUITING | NCT06703632 |
| blood sampling | Other | Approved | Screening for Colon Cancer | RECRUITING | NCT06703632 |
| Survey using a questionnaire. | Other | Approved | Screening for Colon Cancer | RECRUITING | NCT06703632 |
| blood sampling | Other | Approved | Screening for Colon Cancer | RECRUITING | NCT06703632 |
| Survey using a questionnaire. | Other | Approved | Screening for Colon Cancer | RECRUITING | NCT06703632 |
| blood sampling | Other | Approved | Screening for Colon Cancer | RECRUITING | NCT06703632 |
| Quality of life questionnair | Other | Preclinical | Incisional Hernia | ENROLLING_BY_INVITATION | NCT06864377 |
| Quality of life questionnair | Other | Preclinical | Incisional Hernia | ENROLLING_BY_INVITATION | NCT06864377 |
| Quality of life questionnair | Other | Preclinical | Incisional Hernia | ENROLLING_BY_INVITATION | NCT06864377 |
| Increase of physical activity volume and intensity with the use of a motivational smartphone application | Other | Approved | Parkinson Disease | NOT_YET_RECRUITING | NCT06993142 |
| Increase of physical activity volume and intensity with the use of a motivational smartphone application | Other | Approved | Parkinson Disease | NOT_YET_RECRUITING | NCT06993142 |
| Increase of physical activity volume and intensity with the use of a motivational smartphone application | Other | Approved | Parkinson Disease | RECRUITING | NCT06193252 |
| Placebo | Other | Phase PHASE3 | Severe Asthma | NOT_YET_RECRUITING | NCT07013123 |
| Acarizax | Other | Phase PHASE3 | Severe Asthma | NOT_YET_RECRUITING | NCT07013123 |
| Tezepelumab | Other | Phase PHASE3 | Severe Asthma | NOT_YET_RECRUITING | NCT07013123 |
| Placebo | Other | Phase PHASE3 | Severe Asthma | NOT_YET_RECRUITING | NCT07013123 |
| Acarizax | Other | Phase PHASE3 | Severe Asthma | NOT_YET_RECRUITING | NCT07013123 |
| Tezepelumab | Other | Phase PHASE3 | Severe Asthma | NOT_YET_RECRUITING | NCT07013123 |
| C134 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT06614855 |
| C134 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT06614855 |
| C134 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT06614855 |
| MT-601 | Other | Phase PHASE1 | Non-Hodgkin Lymphoma, Adult | RECRUITING | NCT05798897 |
| blood sampling | Other | Preclinical | Colorectal Cancer | RECRUITING | NCT06889844 |
| blood sampling | Other | Preclinical | Colorectal Cancer | RECRUITING | NCT06889844 |
| MT-401 | Other | Phase PHASE2 | Acute Myeloid Leukemia | TERMINATED | NCT04511130 |
| Educational curriculum | Other | Approved | Environmental Exposure | ACTIVE_NOT_RECRUITING | NCT06450951 |
| Urinary EDC metabolite testing | Other | Approved | Environmental Exposure | ACTIVE_NOT_RECRUITING | NCT06450951 |
| Educational curriculum | Other | Approved | Environmental Exposure | ACTIVE_NOT_RECRUITING | NCT06450951 |
| Urinary EDC metabolite testing | Other | Approved | Environmental Exposure | ACTIVE_NOT_RECRUITING | NCT06450951 |
| MT-401-OTS | Other | Phase PHASE1 | Acute Myeloid Leukemia, in Relapse | RECRUITING | NCT06552416 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | ACTIVE_NOT_RECRUITING | NCT07391397 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | ACTIVE_NOT_RECRUITING | NCT07391397 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | ACTIVE_NOT_RECRUITING | NCT07391397 |
| Blood Test and Report Back | Other | Approved | Environmental Health Effects | ACTIVE_NOT_RECRUITING | NCT07391397 |
| Education curriculum | Other | Approved | Environmental Exposure | COMPLETED | NCT07461857 |
| Education curriculum | Other | Approved | Environmental Exposure | COMPLETED | NCT07461857 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss reporting | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Siphox clinic biomarker test | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Urinary EDC metabolite testing | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Weight loss Application | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Educational curriculum | Other | Approved | Obesity &Amp;Amp;Amp; Overweight | ACTIVE_NOT_RECRUITING | NCT07560579 |
| Placebo | DRUG | Phase PHASE3 | Severe Asthma | NOT_YET_RECRUITING | NCT07013123 |
| Acarizax | DRUG | Phase PHASE3 | Severe Asthma | NOT_YET_RECRUITING | NCT07013123 |
| Tezepelumab | DRUG | Phase PHASE3 | Severe Asthma | NOT_YET_RECRUITING | NCT07013123 |
| MT-401-OTS | DRUG | Phase PHASE1 | Acute Myeloid Leukemia, in Relapse | RECRUITING | NCT06552416 |
| Increase of physical activity volume and intensity with the use of a motivational smartphone application | BEHAVIORAL | Approved | Parkinson Disease | NOT_YET_RECRUITING | NCT06993142 |
| MT-601 | BIOLOGICAL | Phase PHASE1 | Pancreas Cancer | NOT_YET_RECRUITING | NCT06549751 |
| Ketamine | DRUG | Phase EARLY_PHASE1 | Healthy | COMPLETED | NCT04928703 |
| MT-401 | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | TERMINATED | NCT04511130 |
| Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol) | DEVICE | Approved | Respiratory Failure | COMPLETED | NCT04358003 |
| Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System | DEVICE | Preclinical | Schizophrenia | COMPLETED | NCT04025502 |
| Adjuvant (GM-CSF) Alone | DRUG | Phase PHASE2 | Platinum Sensitive Ovarian Cancer | TERMINATED | NCT02978222 |
| FRα peptide plus Adjuvant (GM-CSF) | BIOLOGICAL | Phase PHASE2 | Platinum Sensitive Ovarian Cancer | TERMINATED | NCT02978222 |
| Altoida: neuropsychological, MRI, EEG and CSF biomarkers | OTHER | Approved | Alzheimer Disease | COMPLETED | NCT02843529 |
| Durvalumab | BIOLOGICAL | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT02764333 |
| TPIV200 | BIOLOGICAL | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT02764333 |
| High dose FRα vaccine | BIOLOGICAL | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02593227 |
| Cyclophosphamide | DRUG | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02593227 |
| Low dose FRα vaccine | BIOLOGICAL | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02593227 |
| laboratory biomarker analysis | OTHER | Phase PHASE1 | HER2-positive Breast Cancer | COMPLETED | NCT01632332 |
| HER-2/neu peptide vaccine | BIOLOGICAL | Phase PHASE1 | HER2-positive Breast Cancer | COMPLETED | NCT01632332 |
Total products: 399